论文部分内容阅读
目的了解希罗达对胃肠癌患者的化疗效果。方法回顾性分析本院收治的37例胃肠癌患者的临床资料,均口服1250 mg/m2希罗达,2次/d,持续治疗42 d(即为1个疗程),执行WHO实施的实体肿瘤疗效评价标准,评价临床治疗效果。结果在对37例患者进行治疗后,完全缓解0例,部分缓解11例,稳定17例,进展9例,总有效率为29.73%,受益率为75.68%,患者不良反应多为Ⅰ级与Ⅱ级。结论希罗达在胃肠癌治疗中具有重要的应用价值与意义,不良反应相对较少,值得临床广泛推广与应用。
Objective To understand the effect of Xeloda on patients with gastrointestinal cancer. Methods The clinical data of 37 patients with gastrointestinal cancer admitted to our hospital were retrospectively analyzed. All patients were treated with 1250 mg / m2 Xeloda orally for 2 d / d for 42 days (ie, one course of treatment), and the WHO entity Tumor evaluation criteria to evaluate the clinical effect. Results After the treatment of 37 patients, complete remission in 0 cases, partial remission in 11 cases, stable in 17 cases, 9 cases of progression, the total effective rate was 29.73%, the rate of benefit was 75.68%, the patients with adverse reactions were mostly grade Ⅰ and Ⅱ level. Conclusion Xeloda in the treatment of gastrointestinal cancer has an important value and significance, relatively few adverse reactions, it is widely recommended and widely used in clinical practice.